Guillain-Barré syndrome after BNT162b2 (Pfizer-BioNTec) vaccination

QJM. 2022 May 10;115(5):331-333. doi: 10.1093/qjmed/hcac102.

Authors

K Takahashi¹, Y Tomoda¹, S Kadena¹, T Kanbayashi², S Kobayashi², R Kato¹

Affiliations

¹ From the Department of General Medicine, Itabashi Chuo Medical Center, 2-12-7 Azusawa, Itabashi-ku, Tokyo 174-0051, Japan.
² Department of Neurology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8606, Japan.

PMID: 35426946
DOI: 10.1093/qjmed/hcac102

No abstract available

MeSH terms

BNT162 Vaccine*
Guillain-Barre Syndrome* / etiology
Humans
Vaccination / adverse effects

Substances

BNT162 Vaccine